Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 8-K Event Results of operations · Executive or director change
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Grant or award President and CEO acquired 5 shares (grant or award)
  6. SC 13G Stake Amended Statement of Ownership
  7. SC 13G Stake Amended Statement of Ownership
  8. SC 13G/A Stake Amended Statement of Ownership
  9. SC 13G Stake Amended Statement of Ownership
  10. SC 13G Stake Amended Statement of Ownership
  11. 8-K Event Material agreement · Unregistered share sale · Regulation FD disclosure
  12. 3 Insider Initial Statement of Ownership
  13. SC 13G/A Stake Amended Statement of Ownership
  14. SC 13G Stake Amended Statement of Ownership
  15. 4 Open-market buy 10% owner bought 275,000 shares at $18.00 ($4,950,000)
  16. 4 Conversion See Remark 1 acquired 3,273,807 shares (conversion)
  17. 4 Conversion See Remark 1 acquired 3,238,676 shares (conversion)
  18. 4 Conversion 10% owner acquired 8,606,249 shares (conversion)
  19. 4 Conversion 10% owner acquired 10,756,249 shares (conversion)
  20. 4 Conversion Director acquired 25,000 shares (conversion)

Page 37 of 40 · 789 filings